Reinhard von Roemeling

Director Técnico/Científico/I+D en CURIS, INC. .

Health Technology

Consumer Services

Perfil

Reinhard von Roemeling is currently the Senior Vice President-Clinical Development at Curis, Inc. He was previously the Global Head-Research & Development at HUYA Bioscience International LLC.
Dr. von Roemeling holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main.

Cargos activos de Reinhard von Roemeling

Empresas	Cargo	Inicio
CURIS, INC.	Director Técnico/Científico/I+D	13/08/2019

Todos los cargos activos de Reinhard von Roemeling

Antiguos cargos conocidos de Reinhard von Roemeling.

Empresas	Cargo	Fin
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Director Técnico/Científico/I+D	-

Ver el detalle de la experiencia de Reinhard von Roemeling.

Formación de Reinhard von Roemeling.

Johann Wolfgang Goethe-Universität Frankfurt am Main

Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Reinhard von Roemeling.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
CURIS, INC.	Health Technology

Empresas privadas	1
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Health Technology